Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
Idrx has raised $120.0M in total funding. The most recent round was Series B. The last funding was announced in August 2024.
Idrx's investors include Andreessen Horowitz, RA Capital Management, Blackstone Group, Commodore Capital, Nextech Invest.
Idrx is headquartered in Cambridge, United States.
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
Idrx is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Idrx — Funding & Investors." VCBacked, August 7, 2024, https://www.vcbacked.co/company/idrx. Accessed October 31, 2026.
VCBacked. (2024). Idrx — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/idrx
{{cite web |title=Idrx — Funding & Investors |url=https://www.vcbacked.co/company/idrx |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated